- Home
- BCAB vs TLSA Comparison
BCAB vs TLSA Comparison
Compare BCAB & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- TLSA
- Stock Information
- Founded
- BCAB 2007
- TLSA 2013
- Country
- BCAB United States
- TLSA United Kingdom
- Employees
- BCAB N/A
- TLSA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- TLSA Health Care
- Exchange
- BCAB Nasdaq
- TLSA Nasdaq
- Market Cap
- BCAB 22.3M
- TLSA 187.0M
- IPO Year
- BCAB 2020
- TLSA 2000
- Fundamental
- Price
- BCAB $0.38
- TLSA $1.45
- Analyst Decision
- BCAB Buy
- TLSA
- Analyst Count
- BCAB 2
- TLSA 0
- Target Price
- BCAB $1.00
- TLSA N/A
- AVG Volume (30 Days)
- BCAB 541.7K
- TLSA 246.7K
- Earning Date
- BCAB 08-07-2025
- TLSA 07-22-2025
- Dividend Yield
- BCAB N/A
- TLSA N/A
- EPS Growth
- BCAB N/A
- TLSA N/A
- EPS
- BCAB N/A
- TLSA N/A
- Revenue
- BCAB $11,000,000.00
- TLSA N/A
- Revenue This Year
- BCAB N/A
- TLSA N/A
- Revenue Next Year
- BCAB N/A
- TLSA N/A
- P/E Ratio
- BCAB N/A
- TLSA N/A
- Revenue Growth
- BCAB N/A
- TLSA N/A
- 52 Week Low
- BCAB $0.24
- TLSA $0.63
- 52 Week High
- BCAB $2.53
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- BCAB 44.12
- TLSA 48.43
- Support Level
- BCAB $0.36
- TLSA $1.43
- Resistance Level
- BCAB $0.42
- TLSA $1.81
- Average True Range (ATR)
- BCAB 0.03
- TLSA 0.09
- MACD
- BCAB -0.00
- TLSA -0.02
- Stochastic Oscillator
- BCAB 29.75
- TLSA 18.53
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.